Pliant Therapeutics (NASDAQ:PLRX) Chief Operating Officer Minnie Kuo sold 6,917 shares of common stock on January 20, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $1.28, totaling $8,853. This transaction comes as PLRX shares have fallen 88% over the past year, with the stock currently trading at $1.30, significantly below its 52-week high of $12.88. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.
the price range for the shares sold ranged from $1.245 to $1.33. following the transaction, kuo directly owns 37,806 shares of pliant therapeutics.
Represents a nondiscretionary sale by the plan on behalf of the reporting person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the reporting person’s share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the issuer, including the reporting person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The reporting person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the issuer at each separate price within the range set forth in footnote (1) to this Form 4.
In other recent news, Pliant Therapeutics reported positive interim results from its Phase 1 trial of the cancer drug PLN-101095. The trial, which involved combining PLN-101095 with pembrolizumab, showed one confirmed complete response and three partial responses among patients with advanced or metastatic solid tumors that were refractory to immune checkpoint inhibitors. This promising development was observed across several cancer types, including cholangiocarcinoma and melanoma. Meanwhile, Pliant Therapeutics announced several leadership changes, including the appointment of Minnie Kuo as Chief Operating Officer and the resignation of Chief Business Officer Hans Hull. Additionally, the company notified Dr. Éric Lefebvre, Chief Medical Officer, of the end of his employment, although he will continue as a consultant to assist with the transition. These developments were disclosed in recent SEC filings and press releases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read more on Investing.com India
